Short Interest in Trinity Biotech PLC (NASDAQ:TRIB) Declines By 74.3%

Posted by Geri Gentry on Jul 26th, 2026

Trinity Biotech PLC (NASDAQ:TRIB – Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 364,403 shares, a decrease of 74.3% from the June 30th total of 1,417,438 shares. Approximately 11.1% of the company’s stock are sold short. Based on an average trading volume of 497,743 shares, the days-to-cover ratio is presently 0.7 days.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Trinity Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Trinity Biotech presently has an average rating of “Reduce”.

Check Out Our Latest Report on Trinity Biotech

Trinity Biotech Trading Down 5.7%

NASDAQ:TRIB traded down $0.51 on Friday, reaching $8.45. The stock had a trading volume of 23,862 shares. The company has a 50-day moving average of $0.67 and a 200 day moving average of $0.69. The stock has a market cap of $1.01 million and a P/E ratio of -0.16. Trinity Biotech has a 12-month low of $8.00 and a 12-month high of $103.20.

Trinity Biotech (NASDAQ:TRIB – Get Free Report) last announced its earnings results on Tuesday, June 16th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. The business had revenue of $10.85 million for the quarter, compared to analysts’ expectations of $10.68 million.

Institutional Investors Weigh In On Trinity Biotech

Hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC raised its position in shares of Trinity Biotech by 196.1% in the 3rd quarter. Citadel Advisors LLC now owns 39,384 shares of the company’s stock valued at $41,000 after purchasing an additional 26,084 shares in the last quarter. Williams & Novak LLC increased its stake in shares of Trinity Biotech by 677.5% in the fourth quarter. Williams & Novak LLC now owns 93,300 shares of the company’s stock worth $74,000 after buying an additional 81,300 shares during the last quarter. Yorkville Advisors Global LP acquired a new stake in Trinity Biotech in the first quarter valued at $122,000. Hunter Associates Investment Management LLC raised its holdings in Trinity Biotech by 8.1% in the fourth quarter. Hunter Associates Investment Management LLC now owns 526,610 shares of the company’s stock valued at $417,000 after acquiring an additional 39,500 shares in the last quarter. Finally, Perceptive Advisors LLC bought a new position in Trinity Biotech during the 2nd quarter valued at $1,164,000. 78.97% of the stock is currently owned by hedge funds and other institutional investors.

Trinity Biotech Company Profile

(Get Free Report)

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.